Incidence and Impact of COVID-19 in MS: A Survey From a Barcelona MS Unit.

Adult Aged Aged, 80 and over Antirheumatic Agents / adverse effects COVID-19 / complications Cohort Studies Comorbidity Cross-Sectional Studies Electronic Health Records Female Hospitalization Humans Incidence Male Middle Aged Multiple Sclerosis / complications Sex Factors Spain / epidemiology Surveys and Questionnaires Treatment Outcome Young Adult

Journal

Neurology(R) neuroimmunology & neuroinflammation
ISSN: 2332-7812
Titre abrégé: Neurol Neuroimmunol Neuroinflamm
Pays: United States
ID NLM: 101636388

Informations de publication

Date de publication:
04 03 2021
Historique:
received: 22 09 2020
accepted: 20 11 2020
entrez: 28 1 2021
pubmed: 29 1 2021
medline: 5 2 2021
Statut: epublish

Résumé

To investigate the incidence of coronavirus disease 2019 (COVID-19) in a single-center cohort of patients with MS and to explore the contribution of their comorbidities and therapies to the outcome. A cross-sectional mixed-method study was conducted involving an email-based, self-administered questionnaire sent on May 21, 2020, to 586 patients with MS followed at the MS Unit of Hospital Clinic, University of Barcelona, along with telephone interview, and review of electronic medical records until June 18, 2020. The cumulative incidence of confirmed COVID-19 (positive PCR or antibody test) and all COVID-19 cases (confirmed and suspected) from the start of the pandemic was compared with the population estimates for Barcelona. A total of 407 patients (69.5%) completed the survey. Most of the responders (67%) were female. The responders had a median age of 48 years (range 19-86), relapsing-remitting disease (84%), at least 1 comorbidity (45%), and were on disease-modifying therapy (DMT; 74.7%). COVID-19 was confirmed in 5 patients (1.2%) and suspected in 46 (11.3%). The cumulative incidence of confirmed COVID-19 cases was similar to that of the general population but was almost 2-fold higher when all cases were considered ( In the studied MS cohort, the incidence of COVID-19 was higher than that of the general population; however, most patients did not require hospitalization and had a good outcome despite the frequent presence of comorbidities and treatment with DMT.

Identifiants

DOI: 10.1212/NXI.0000000000000954 PMID: 33504634 PMC: PMC7862095
pubmed: 33504634
pii: 8/2/e954
doi: 10.1212/NXI.0000000000000954
pmc: PMC7862095
pii:
doi:

Substances chimiques

Antirheumatic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Références

Neurology. 2020 Jun 2;94(22):949-952
pubmed: 32241953
Lancet Neurol. 2020 Jun;19(6):481-482
pubmed: 32359409
Neurol Neuroimmunol Neuroinflamm. 2020 Jul 9;7(5):
pubmed: 32646885
Mult Scler. 2020 Sep;26(10):1163-1171
pubmed: 32772807
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
J Neurol Neurosurg Psychiatry. 2020 Aug 27;:
pubmed: 32855290
Mult Scler. 2020 Sep;26(10):1256-1260
pubmed: 32662742
Semin Arthritis Rheum. 2020 Aug;50(4):564-570
pubmed: 32425260
Mult Scler Relat Disord. 2020 Sep;44:102372
pubmed: 32650121
JAMA Neurol. 2020 Sep 1;77(9):1079-1088
pubmed: 32589189
Mult Scler Relat Disord. 2020 Nov;46:102472
pubmed: 32890817
Neurol Neuroimmunol Neuroinflamm. 2020 May 15;7(4):
pubmed: 32414755
Neurol Neuroimmunol Neuroinflamm. 2020 Jun 4;7(5):
pubmed: 32503092
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076

Auteurs

Maria Sepúlveda (M)

From the Neuroimmunology and Multiple Sclerosis Unit (M.S., S.L., E. Martínez-Hernández, M. Artola, A.H., C.M., I.P.-V., E. Martínez-Heras, M.G., E.S., L.L., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Universitat de Barcelona; Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) (M.C., C.P.), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol; Department of Physics (M.C., C.P.), Universitat Politècnica de Catalunya; Preventive Medicine and Epidemiology Department (M. Aldea), Hospital Clinic of Barcelona, University of Barcelona; Neuroimmunology Program (F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); and Institut de Neurociències (A.S.), Universitat de Barcelona, Spain.
ORCID: 0000-0002-3078-645X

Sara Llufriu (S)

From the Neuroimmunology and Multiple Sclerosis Unit (M.S., S.L., E. Martínez-Hernández, M. Artola, A.H., C.M., I.P.-V., E. Martínez-Heras, M.G., E.S., L.L., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Universitat de Barcelona; Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) (M.C., C.P.), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol; Department of Physics (M.C., C.P.), Universitat Politècnica de Catalunya; Preventive Medicine and Epidemiology Department (M. Aldea), Hospital Clinic of Barcelona, University of Barcelona; Neuroimmunology Program (F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); and Institut de Neurociències (A.S.), Universitat de Barcelona, Spain.

Eugenia Martínez-Hernández (E)

From the Neuroimmunology and Multiple Sclerosis Unit (M.S., S.L., E. Martínez-Hernández, M. Artola, A.H., C.M., I.P.-V., E. Martínez-Heras, M.G., E.S., L.L., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Universitat de Barcelona; Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) (M.C., C.P.), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol; Department of Physics (M.C., C.P.), Universitat Politècnica de Catalunya; Preventive Medicine and Epidemiology Department (M. Aldea), Hospital Clinic of Barcelona, University of Barcelona; Neuroimmunology Program (F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); and Institut de Neurociències (A.S.), Universitat de Barcelona, Spain.

Martí Català (M)

From the Neuroimmunology and Multiple Sclerosis Unit (M.S., S.L., E. Martínez-Hernández, M. Artola, A.H., C.M., I.P.-V., E. Martínez-Heras, M.G., E.S., L.L., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Universitat de Barcelona; Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) (M.C., C.P.), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol; Department of Physics (M.C., C.P.), Universitat Politècnica de Catalunya; Preventive Medicine and Epidemiology Department (M. Aldea), Hospital Clinic of Barcelona, University of Barcelona; Neuroimmunology Program (F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); and Institut de Neurociències (A.S.), Universitat de Barcelona, Spain.

Montse Artola (M)

From the Neuroimmunology and Multiple Sclerosis Unit (M.S., S.L., E. Martínez-Hernández, M. Artola, A.H., C.M., I.P.-V., E. Martínez-Heras, M.G., E.S., L.L., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Universitat de Barcelona; Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) (M.C., C.P.), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol; Department of Physics (M.C., C.P.), Universitat Politècnica de Catalunya; Preventive Medicine and Epidemiology Department (M. Aldea), Hospital Clinic of Barcelona, University of Barcelona; Neuroimmunology Program (F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); and Institut de Neurociències (A.S.), Universitat de Barcelona, Spain.

Ana Hernando (A)

From the Neuroimmunology and Multiple Sclerosis Unit (M.S., S.L., E. Martínez-Hernández, M. Artola, A.H., C.M., I.P.-V., E. Martínez-Heras, M.G., E.S., L.L., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Universitat de Barcelona; Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) (M.C., C.P.), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol; Department of Physics (M.C., C.P.), Universitat Politècnica de Catalunya; Preventive Medicine and Epidemiology Department (M. Aldea), Hospital Clinic of Barcelona, University of Barcelona; Neuroimmunology Program (F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); and Institut de Neurociències (A.S.), Universitat de Barcelona, Spain.

Carmen Montejo (C)

From the Neuroimmunology and Multiple Sclerosis Unit (M.S., S.L., E. Martínez-Hernández, M. Artola, A.H., C.M., I.P.-V., E. Martínez-Heras, M.G., E.S., L.L., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Universitat de Barcelona; Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) (M.C., C.P.), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol; Department of Physics (M.C., C.P.), Universitat Politècnica de Catalunya; Preventive Medicine and Epidemiology Department (M. Aldea), Hospital Clinic of Barcelona, University of Barcelona; Neuroimmunology Program (F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); and Institut de Neurociències (A.S.), Universitat de Barcelona, Spain.

Irene Pulido-Valdeolivas (I)

From the Neuroimmunology and Multiple Sclerosis Unit (M.S., S.L., E. Martínez-Hernández, M. Artola, A.H., C.M., I.P.-V., E. Martínez-Heras, M.G., E.S., L.L., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Universitat de Barcelona; Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) (M.C., C.P.), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol; Department of Physics (M.C., C.P.), Universitat Politècnica de Catalunya; Preventive Medicine and Epidemiology Department (M. Aldea), Hospital Clinic of Barcelona, University of Barcelona; Neuroimmunology Program (F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); and Institut de Neurociències (A.S.), Universitat de Barcelona, Spain.

Eloy Martínez-Heras (E)

From the Neuroimmunology and Multiple Sclerosis Unit (M.S., S.L., E. Martínez-Hernández, M. Artola, A.H., C.M., I.P.-V., E. Martínez-Heras, M.G., E.S., L.L., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Universitat de Barcelona; Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) (M.C., C.P.), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol; Department of Physics (M.C., C.P.), Universitat Politècnica de Catalunya; Preventive Medicine and Epidemiology Department (M. Aldea), Hospital Clinic of Barcelona, University of Barcelona; Neuroimmunology Program (F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); and Institut de Neurociències (A.S.), Universitat de Barcelona, Spain.

Mar Guasp (M)

From the Neuroimmunology and Multiple Sclerosis Unit (M.S., S.L., E. Martínez-Hernández, M. Artola, A.H., C.M., I.P.-V., E. Martínez-Heras, M.G., E.S., L.L., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Universitat de Barcelona; Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) (M.C., C.P.), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol; Department of Physics (M.C., C.P.), Universitat Politècnica de Catalunya; Preventive Medicine and Epidemiology Department (M. Aldea), Hospital Clinic of Barcelona, University of Barcelona; Neuroimmunology Program (F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); and Institut de Neurociències (A.S.), Universitat de Barcelona, Spain.

Elisabeth Solana (E)

From the Neuroimmunology and Multiple Sclerosis Unit (M.S., S.L., E. Martínez-Hernández, M. Artola, A.H., C.M., I.P.-V., E. Martínez-Heras, M.G., E.S., L.L., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Universitat de Barcelona; Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) (M.C., C.P.), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol; Department of Physics (M.C., C.P.), Universitat Politècnica de Catalunya; Preventive Medicine and Epidemiology Department (M. Aldea), Hospital Clinic of Barcelona, University of Barcelona; Neuroimmunology Program (F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); and Institut de Neurociències (A.S.), Universitat de Barcelona, Spain.

Laura Llansó (L)

From the Neuroimmunology and Multiple Sclerosis Unit (M.S., S.L., E. Martínez-Hernández, M. Artola, A.H., C.M., I.P.-V., E. Martínez-Heras, M.G., E.S., L.L., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Universitat de Barcelona; Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) (M.C., C.P.), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol; Department of Physics (M.C., C.P.), Universitat Politècnica de Catalunya; Preventive Medicine and Epidemiology Department (M. Aldea), Hospital Clinic of Barcelona, University of Barcelona; Neuroimmunology Program (F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); and Institut de Neurociències (A.S.), Universitat de Barcelona, Spain.

Domingo Escudero (D)

From the Neuroimmunology and Multiple Sclerosis Unit (M.S., S.L., E. Martínez-Hernández, M. Artola, A.H., C.M., I.P.-V., E. Martínez-Heras, M.G., E.S., L.L., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Universitat de Barcelona; Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) (M.C., C.P.), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol; Department of Physics (M.C., C.P.), Universitat Politècnica de Catalunya; Preventive Medicine and Epidemiology Department (M. Aldea), Hospital Clinic of Barcelona, University of Barcelona; Neuroimmunology Program (F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); and Institut de Neurociències (A.S.), Universitat de Barcelona, Spain.

Marta Aldea (M)

From the Neuroimmunology and Multiple Sclerosis Unit (M.S., S.L., E. Martínez-Hernández, M. Artola, A.H., C.M., I.P.-V., E. Martínez-Heras, M.G., E.S., L.L., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Universitat de Barcelona; Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) (M.C., C.P.), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol; Department of Physics (M.C., C.P.), Universitat Politècnica de Catalunya; Preventive Medicine and Epidemiology Department (M. Aldea), Hospital Clinic of Barcelona, University of Barcelona; Neuroimmunology Program (F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); and Institut de Neurociències (A.S.), Universitat de Barcelona, Spain.

Clara Prats (C)

From the Neuroimmunology and Multiple Sclerosis Unit (M.S., S.L., E. Martínez-Hernández, M. Artola, A.H., C.M., I.P.-V., E. Martínez-Heras, M.G., E.S., L.L., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Universitat de Barcelona; Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) (M.C., C.P.), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol; Department of Physics (M.C., C.P.), Universitat Politècnica de Catalunya; Preventive Medicine and Epidemiology Department (M. Aldea), Hospital Clinic of Barcelona, University of Barcelona; Neuroimmunology Program (F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); and Institut de Neurociències (A.S.), Universitat de Barcelona, Spain.

Francesc Graus (F)

From the Neuroimmunology and Multiple Sclerosis Unit (M.S., S.L., E. Martínez-Hernández, M. Artola, A.H., C.M., I.P.-V., E. Martínez-Heras, M.G., E.S., L.L., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Universitat de Barcelona; Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) (M.C., C.P.), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol; Department of Physics (M.C., C.P.), Universitat Politècnica de Catalunya; Preventive Medicine and Epidemiology Department (M. Aldea), Hospital Clinic of Barcelona, University of Barcelona; Neuroimmunology Program (F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); and Institut de Neurociències (A.S.), Universitat de Barcelona, Spain.

Yolanda Blanco (Y)

From the Neuroimmunology and Multiple Sclerosis Unit (M.S., S.L., E. Martínez-Hernández, M. Artola, A.H., C.M., I.P.-V., E. Martínez-Heras, M.G., E.S., L.L., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Universitat de Barcelona; Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) (M.C., C.P.), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol; Department of Physics (M.C., C.P.), Universitat Politècnica de Catalunya; Preventive Medicine and Epidemiology Department (M. Aldea), Hospital Clinic of Barcelona, University of Barcelona; Neuroimmunology Program (F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); and Institut de Neurociències (A.S.), Universitat de Barcelona, Spain.

Albert Saiz (A)

From the Neuroimmunology and Multiple Sclerosis Unit (M.S., S.L., E. Martínez-Hernández, M. Artola, A.H., C.M., I.P.-V., E. Martínez-Heras, M.G., E.S., L.L., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Universitat de Barcelona; Comparative Medicine and Bioimage Centre of Catalonia (CMCiB) (M.C., C.P.), Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol; Department of Physics (M.C., C.P.), Universitat Politècnica de Catalunya; Preventive Medicine and Epidemiology Department (M. Aldea), Hospital Clinic of Barcelona, University of Barcelona; Neuroimmunology Program (F.G.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS); and Institut de Neurociències (A.S.), Universitat de Barcelona, Spain. asaiz@clinic.cat.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Incidence and Impact of COVID-19 in MS: A...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Incidence and Impact of COVID-19 in MS: A...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Incidence and Impact of COVID-19 in MS: A...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antirhumatismaux › Incidence and Impact of COVID-19 in MS: A...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Incidence and Impact of COVID-19 in MS: A...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Incidence and Impact of COVID-19 in MS: A...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Facteurs épidémiologiques › Comorbidité › Incidence and Impact of COVID-19 in MS: A...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études transversales › Incidence and Impact of COVID-19 in MS: A...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Documents › Dossiers médicaux › Systèmes informatisés de dossiers médicaux › Dossiers médicaux électroniques › Incidence and Impact of COVID-19 in MS: A...
questionsmedicales.fr › Établissements, main d'oeuvre et services de soins de santé › Services de santé › Soins aux patients › Hospitalisation › Incidence and Impact of COVID-19 in MS: A...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Incidence and Impact of COVID-19 in MS: A...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Incidence › Incidence and Impact of COVID-19 in MS: A...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Incidence and Impact of COVID-19 in MS: A...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Maladies auto-immunes du système nerveux › Maladies démyélinisantes auto-immunes du SNC › Sclérose en plaques › Incidence and Impact of COVID-19 in MS: A...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Facteurs épidémiologiques › Facteurs sexuels › Incidence and Impact of COVID-19 in MS: A...
questionsmedicales.fr › Régions géographiques › Europe › Espagne › Incidence and Impact of COVID-19 in MS: A...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enquêtes et questionnaires › Incidence and Impact of COVID-19 in MS: A...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Incidence and Impact of COVID-19 in MS: A...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Jeune adulte › Incidence and Impact of COVID-19 in MS: A...